![Jason Keyes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason Keyes
Direktor/Vorstandsmitglied bei
ACTUATE THERAPEUTICS, INC.
Vermögen: 367 236 $ am 31.05.2026
Profil
Jason A. Keyes is currently an Independent Director at Actuate Therapeutics, Inc. since 2024.
Formerly, Mr. Keyes was Senior Director-Finance at Amylin Pharmaceuticals, Inc. from 2007 to 2013.
Served as Independent Director at Sesen Bio, Inc. from 2020 to 2023.
Held the position of Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc. from 2016 to 2018.
Worked at Amgen, Inc. as Head-Finance & Strategy.
Was Chief Financial Officer at Equillium, Inc. from 2018 to 2025.
Education includes undergraduate and graduate degrees from Stanford University and an MBA from UCLA Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EQUILLIUM, INC. 0,2 % | 14.02.2025 | 126.633 ( 0,2 % ) | 367 236 $ | 31.05.2026 |
| 21.05.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Jason Keyes
| Unternehmen | Position | Beginn |
|---|---|---|
| ACTUATE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 12.08.2024 |
Ehemalige bekannte Positionen von Jason Keyes
| Unternehmen | Position | Ende |
|---|---|---|
| EQUILLIUM, INC. | Finanzdirektor/CFO | 25.04.2025 |
| CARISMA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 07.03.2023 |
| OREXIGEN THERAPEUTICS, INC. | Finanzdirektor/CFO | 23.02.2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Finanzdirektor/CFO | 01.01.2013 |
| AMGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Jason Keyes
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
56
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on the treatment of obesity | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
UCLA Anderson School of Management
 UCLA Anderson School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Actuate Therapeutics, Inc.
 Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel therapeutics which target cancers and neurodegenerative diseases | Health Technology |
Equillium, Inc.
 Equillium, Inc. BiotechnologyHealth Technology Engages in the development of products for severe immune-inflammatory disorders | Health Technology |
